NRX-100
Suicidal Depression
NDA SubmissionANDA filed; NDA submission initiated; FDA Bioequivalence determination received
Key Facts
Indication
Suicidal Depression
Phase
NDA Submission
Status
ANDA filed; NDA submission initiated; FDA Bioequivalence determination received
Company
About NRx Pharmaceuticals
NRx Pharmaceuticals is a public company (Nasdaq: NRXP) focused on developing life-saving treatments for suicidal depression, bipolar depression, and PTSD. Its core technology targets the brain's NMDA and 5-HT2A receptors with a non-hallucinogenic, non-addictive approach. Key achievements include positive Phase 2 data for NRX-101, FDA designations for its lead program, and the submission of an ANDA for NRX-100, positioning it as a leader in neuroplastic therapies for severe mental health crises.
View full company profile